Effects of liraglutide on metabolic syndrome in WBN/Kob diabetic fatty rats supplemented with a high‐fat diet

Effects of liraglutide on metabolic syndrome in WBN/Kob diabetic fatty rats supplemented with a high‐fat diet

Abstract Background Liraglutide, a GLP‐1 receptor agonist, has recently been used to treat metabolic syndrome (MS) because of its anti‐diabetic and anti‐obesity effects. We have previously shown that Wistar Bonn Kobori diabetic and fatty (WBN/Kob‐Leprfa, WBKDF) rats fed a high‐fat diet (HFD) develop...

Full description

Bibliographic Details
Main Authors: Noriyuki Kaji, Yoshiichi Takagi, Satomi Matsuda, Anna Takahashi, Sakurako Fujio, Fumitoshi Asai
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:Animal Models and Experimental Medicine
Subjects:
diabetes mellitus
liraglutide
metabolic syndrome
models
animal
obesity
Online Access:https://doi.org/10.1002/ame2.12106

Internet

https://doi.org/10.1002/ame2.12106

Similar Items